World Journal of Urology

, Volume 32, Issue 5, pp 1251–1257 | Cite as

The relationship between solar UV exposure, serum vitamin D levels and serum prostate-specific antigen levels, in men from New South Wales, Australia: the CHAMP study

  • Visalini Nair-Shalliker
  • David P. Smith
  • Mark Clements
  • Vasikaran Naganathan
  • Melisa Litchfield
  • Louise Waite
  • David Handelsman
  • Markus J. Seibel
  • Robert Cumming
  • Bruce K. Armstrong
Original Article

Abstract

Purpose

We aim to determine the relationship between season, personal solar UV exposure, serum 25(OH)D and 1,25(OH)2D and serum prostate-specific antigen (PSA) levels.

Methods

Questionnaire data and blood samples were collected at baseline from participants of the Concord Health and Ageing in Men Project (n = 1,705), aged 70 and above. They were grouped as men ‘free of prostate disease’ for those with no record of having prostate cancer, benign prostatic hyperplasia, or prostatitis and with serum PSA levels below 20 ng/mL, and ‘with prostate disease’ for those with a record of either of these diseases or with serum PSA levels 20 ng/mL or above. Personal solar UV exposure (sUV) was estimated from recalled hours of outdoor exposure and weighted against ambient solar UV radiation. Sera were analysed to determine levels of PSA, 25(OH)D and 1,25(OH)2D, and analysed using multiple regression, adjusting for age, BMI and region of birth.

Results

The association between sUV and serum PSA levels was conditional upon season (p interaction  = 0.04). There was no direct association between serum PSA and 25(OH)D in both groups of men. There was a positive association between serum PSA and 1,25(OH)2D in men with prostate disease (mean = 110.6 pmol/L; p heterogeneity = 0.03), but there was no such association in men free of prostate disease (mean = 109.3 pmol/L; p heterogeneity = 0.8).

Conclusion

The association between PSA and sUV may only be evident at low solar UV irradiance, and this effect may be independent of serum vitamin D levels.

Keywords

Season Solar UV 25(OH)D 1,25(OH)2PSA Australia 

Abbreviations

sUV

Personal solar UV exposure

NSW

New South Wales

CHAMP

The Concord Health and Ageing in Men Project

PSA

Prostate-specific antigen

PTH

Parathyroid hormone

ERSPC

European Randomised study of Screening for Prostate Cancer

Notes

Acknowledgments

This study was funded by the Cancer Council New South Wales project Grant (512513).

Conflict of interest

There is no conflict of interest for any of the authors.

Supplementary material

345_2013_1201_MOESM1_ESM.tif (116 kb)
Supplementary material 1 (TIFF 115 kb)
345_2013_1201_MOESM2_ESM.tif (89 kb)
Supplementary material 2 (TIFF 88 kb)
345_2013_1201_MOESM3_ESM.docx (28 kb)
Supplementary material 3 (DOCX 28 kb)

References

  1. 1.
    Schroder FH (2009) Review of diagnostic markers for prostate cancer. Recent Results Cancer Res 181:173–182PubMedCrossRefGoogle Scholar
  2. 2.
    Vieth R, Choo R, Deboer L, Danjoux C, Morton G, Klotz L (2006) Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer. Am J Ther 13:394–399PubMedCrossRefGoogle Scholar
  3. 3.
    Lujan GM, Pascual MC, Rodriguez GN, Garcia Mediero JM, Pascual DT, Paez BA, Berenguer SA (2006) Impact of the weather on the serum levels of prostatic specific antigen (PSA). Arch Esp Urol 59:247–252Google Scholar
  4. 4.
    Salama G, Noirot O, Bataille V, Malavaud S, Rebillard X, Villers A et al (2007) Seasonality of serum prostate-specific antigen levels: a population-based study. Eur Urol 52(3):708–714Google Scholar
  5. 5.
    Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K (2006) Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clin Cancer Res 12:2812–2816PubMedCrossRefGoogle Scholar
  6. 6.
    Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796–804PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035–2039PubMedCrossRefGoogle Scholar
  8. 8.
    Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255–265PubMedCrossRefGoogle Scholar
  9. 9.
    Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kroger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larranaga N, Gonzalez CA, Arguelles MV, Sanchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ (2009) Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 169:1223–1232PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Woo TC, Choo R, Jamieson M, Chander S, Vieth R (2005) Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 51:32–36PubMedCrossRefGoogle Scholar
  11. 11.
    Skinner HG, Schwartz GG (2009) The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study. Cancer Epidemiol Biomarkers Prev 18:2869–2873PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Cumming RG, Handelsman D, Seibel MJ, Creasey H, Sambrook P, Waite L, Naganathan V, Le CD, Litchfield M (2009) Cohort profile: the Concord health and ageing in men project (CHAMP). Int J Epidemiol 38:374–378PubMedCrossRefGoogle Scholar
  13. 13.
    Litchfield MJ, Cumming RG, Smith DP, Naganathan V, Le Couteur DG, Waite LM, Blyth FM, Handelsman DJ (2012) Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study. Med J Aust 196:395–398PubMedGoogle Scholar
  14. 14.
    Need AG, Kemp A, Giles N, Morris HA, Horowitz M, Nordin BE (2002) Relationships between intestinal calcium absorption, serum vitamin D metabolites and smoking in postmenopausal women. Osteoporos Int 13:83–88PubMedCrossRefGoogle Scholar
  15. 15.
    Nowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM, Seibel MJ, Mason RS (2012) Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust 196:686–687PubMedCrossRefGoogle Scholar
  16. 16.
    Stolwijk AM, Straatman H, Zielhuis GA (1999) Studying seasonality by using sine and cosine functions in regression analysis. J Epidemiol Community Health 53:235–238PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ferlay J, Parkin DM, Curado MP et al. (2010) Cancer incidence in five continents, volumes I to IX: IARC. Lyon, France: International agency for research on cancer. Available from: http://ci5.iarc.fr
  18. 18.
    Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R (2013) Randomized clinical trial of vitamin D3 doses on prostatic vitamin d metabolite levels and Ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab 98:1498–1507PubMedCrossRefGoogle Scholar
  19. 19.
    Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol 92:4–8PubMedCrossRefGoogle Scholar
  20. 20.
  21. 21.
    Krishnan AV, Peehl DM, Feldman D (2003) The role of vitamin D in prostate cancer. Recent Results Cancer Res 164:205–221PubMedCrossRefGoogle Scholar
  22. 22.
    Zhao XY, Ly LH, Peehl DM, Feldman D (1999) Induction of androgen receptor by 1alpha, 25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205–1212PubMedGoogle Scholar
  23. 23.
    Zhao XY, Peehl DM, Navone NM, Feldman D (2000) 1 alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141:2548–2556PubMedGoogle Scholar
  24. 24.
    Krishnan AV, Peehl DM, Feldman D (2003) Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 88:363–371PubMedCrossRefGoogle Scholar
  25. 25.
    Peehl DM, Krishnan AV, Feldman D (2003) Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133:2461S–2469SPubMedGoogle Scholar
  26. 26.
    Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43–46PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Visalini Nair-Shalliker
    • 1
    • 2
  • David P. Smith
    • 1
    • 3
  • Mark Clements
    • 4
  • Vasikaran Naganathan
    • 5
  • Melisa Litchfield
    • 5
  • Louise Waite
    • 5
  • David Handelsman
    • 6
  • Markus J. Seibel
    • 6
    • 7
  • Robert Cumming
    • 2
    • 5
  • Bruce K. Armstrong
    • 2
  1. 1.Cancer Research DivisionCancer Council New South WalesSydneyAustralia
  2. 2.Sydney School of Public HealthThe University of SydneySydneyAustralia
  3. 3.Griffith Health InstituteGriffith UniversityGold CoastAustralia
  4. 4.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
  5. 5.Centre for Education and Research on Ageing, Concord HospitalUniversity of SydneySydneyAustralia
  6. 6.ANZAC Research InstituteThe University of SydneySydneyAustralia
  7. 7.Department of Endocrinology and MetabolismConcord HospitalSydneyAustralia

Personalised recommendations